DEMERX

demerx-logo

DemeRx develops treatment for drug addiction among patients coping with chronic pain. The company was incorporated in 2010 and is based in Destin, Florida.

#SimilarOrganizations #People #Event #Website #More

DEMERX

Social Links:

Industry:
Health Care Health Diagnostics Medical

Founded:
2010-01-01

Address:
Destin, Florida, United States

Country:
United States

Website Url:
http://www.demerx.com

Total Employee:
11+

Status:
Active

Contact:
(850) 650-1010

Total Funding:
489.57 K USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Apache Global Site Tag


Similar Organizations

ancora-heart-logo

Ancora Heart

Ancora Heart is dedicated to helping people with heart failure feel better and live longer.

celator-pharmaceuticals-logo

Celator Pharmaceuticals

Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.

knopp-biosciences-logo

Knopp Biosciences

Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.

pacylex-logo

Pacylex

Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.

Current Employees Featured

deborah-mash_image

Deborah Mash
Deborah Mash CEO and Founder @ DemeRx
CEO and Founder
2017-07-01

Founder


deborah-mash_image

Deborah Mash

Key Employee Changes

Date New article
2021-02-05 PE-backed Blaze Pizza taps Demery as CTO

Official Site Inspections

http://www.demerx.com Semrush global rank: 4.49 M Semrush visits lastest month: 2.4 K

  • Host name: li1038-203.members.linode.com
  • IP address: 45.33.96.203
  • Location: Atlanta United States
  • Latitude: 33.7485
  • Longitude: -84.3871
  • Metro Code: 524
  • Timezone: America/New_York
  • Postal: 30301

Loading ...

More informations about "DemeRx"

Team โ€“ DemeRx

In 2010, she founded DemeRx with Steve Gorlin to advance clinical development of the metabolite of ibogaine โ€“ Noribogaine. Deborah served as Director and Chief Scientific Officer โ€ฆSee details»

About โ€“ DemeRx

DemeRx plans to develop a daily dose formulation of DMX-1001 (Noribogaine) for the treatment of alcohol use disorder. DemeRx offers licensing of intellectual property in the field of pharmaceuticals. Bridging the research to clinical โ€ฆSee details»

DemeRx - Psychedelic Science Review

DemeRx. DemeRx is a pharmaceutical company focused on develop ing the psychedelic drug ibogaine and its metabolite noribogaine to treat opioid addiction. The company was founded in โ€ฆSee details»

DemeRx - Crunchbase Company Profile & Funding

Organization. DemeRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. DemeRx, Inc. develops treatment for drug โ€ฆSee details»

DemeRx - LinkedIn

DemeRx is excited to announce that Deborah Mash, our CEO, will join global decision makers in life sciences at the Longwood Healthcare Leaders #BostonCEO conference event, on October โ€ฆSee details»

DemeRx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Jul 1, 2023 Explore DemeRx, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 7 news, and 7 literature, Technology Platform:Small molecule ...See details»

DemeRx - Facebook

DemeRx. 592 likes. The DemeRx organization is the fulfilled vision of Deborah C. Mash, PhD. Dr. Mash is arguably the most knowledgeable and foremost expert on the topic of Ibogaine and Noribogaine...See details»

DemeRx Company Profile 2024: Valuation, Investors, Acquisition

DemeRx General Information Description. Operator of a clinical-stage pharmaceutical development company intended for patients suffering from opioid use disorder. The company โ€ฆSee details»

DemeRx - Overview, News & Similar companies | ZoomInfo.com

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai โ€ฆSee details»

DemeRx Company Profile - Office Locations, Competitors, โ€ฆ

DemeRx is a pharmaceutical development company specializing in medication-assisted therapies for opioid addiction. Its lead drug lbogaine is an indole alkaloid that blocks opioid withdrawal โ€ฆSee details»

DemeRx CEO and Key Executive Team | Craft.co

DemeRx's Executive Chairman is Richard S. Serbin. Other executives include Deborah C. Mash, Chief Executive Officer & Founder, Director; Pascal J. Goldschmidt, Chief Medical Officer, โ€ฆSee details»

Noribogaine - DemeRx

DemeRx has secured GMP drug supplies of noribogaine and the company stands ready to work with government and industry partners to address the worldwide alcohol abuse problem. โ€ฆSee details»

DemeRx - Contacts, Employees, Board Members, Advisors

Organization. DemeRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Contacts 4. ... DemeRx โ€ฆSee details»

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 โ€ฆ

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the โ€ฆSee details»

DemeRx 'forging ahead' with atai Life Sciences to dose patients in ...

Oct 12, 2021 DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group's joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine โ€ฆSee details»

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002

Sep 21, 2021 About DemeRx, Inc. & DMX-1002 DemeRx, Inc. is a Miami-based clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of โ€ฆSee details»

10 Psychedelics CEOs To Pay Attention To In 2022 โ€“ DemeRx

Sep 6, 2022 He has led both ASX listed and privately held businesses, delivering products and services through both SaaS and traditional technology platforms in B2B and B2C โ€ฆSee details»

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 โ€ฆ

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) โ€” DemeRx IB, Inc. (โ€œDemeRxโ€), an atai Life Sciences (Nasdaq: ATAI) (โ€œataiโ€) platform company focused on developing ibogaine for the โ€ฆSee details»

News - DemeRx

Jun 26, 2024 Opium Addiction Market expected to rise โ€“ BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, expected to drive market July 26, 2023 Jun 09, 2023 (AB Digital via โ€ฆSee details»

linkstock.net © 2022. All rights reserved